At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BNTC Benitec Biopharma
Trading 02-26 15:22:24 EST
11.06
+0.06
+0.55%
High11.17Low10.65Vol58.85K
Open10.98D1 Closing11.00Amplitude4.73%
Mkt Cap378.86MTradable Cap230.61MTotal Shares34.25M
T/O644.61KT/O Rate0.28%Tradable Shares20.85M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Benitec Biopharma to Present BB-301 Phase 1b/2a Interim Data at Muscular Dystrophy Association Clinical and Scientific Conference
Reuters  ·  02-23
Benitec Biopharma to Present BB-301 Phase 1b/2a Interim Data at Muscular Dystrophy Association Clinical and Scientific Conference
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  02-13
Calendar of U.S. Earnings Expected in the Week Ahead
Benitec Biopharma Q2 EPS $(0.26) Misses $(0.22) Estimate
Benzinga  ·  02-12
Benitec Biopharma Q2 EPS $(0.26) Misses $(0.22) Estimate
Benitec Biopharma reports Q2 EPS (26c) vs (26c) last year
TIPRANKS  ·  02-12
Benitec Biopharma reports Q2 EPS (26c) vs (26c) last year
BRIEF-Benitec Biopharma Q2 Operating Income USD -13.4 Million
Reuters  ·  02-12
BRIEF-Benitec Biopharma Q2 Operating Income USD -13.4 Million
Benitec Biopharma Q2 EPS USD -0.26
THOMSON REUTERS  ·  02-12
Benitec Biopharma Q2 EPS USD -0.26
Press Release: Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update
Dow Jones  ·  02-12
Press Release: Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update
Benitec Biopharma posts Q2 net loss of USD 11.8 million
Reuters  ·  02-12
Benitec Biopharma posts Q2 net loss of USD 11.8 million
Benitec Biopharma files to sell 1.48M shares of common stock for holders
TIPRANKS  ·  01-31
Benitec Biopharma files to sell 1.48M shares of common stock for holders
Benitec Biopharma Reports Durable Efficacy for BB-301 in OPMD Phase 1b/2a Trial
Reuters  ·  01-11
Benitec Biopharma Reports Durable Efficacy for BB-301 in OPMD Phase 1b/2a Trial
Benitec Biopharma Provides Positive Long-Term Clinical Study Results for Bb-301 Phase 1B/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response
THOMSON REUTERS  ·  01-11
Benitec Biopharma Provides Positive Long-Term Clinical Study Results for Bb-301 Phase 1B/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response
Benitec Biopharma Unveils Gene Therapy Breakthrough for OPMD-Related Dysphagia
Reuters  ·  01-11
Benitec Biopharma Unveils Gene Therapy Breakthrough for OPMD-Related Dysphagia
Suvretta Capital Management Reports Acquisition of Benitec Biopharma Common Shares
Reuters  ·  2025-12-30
Suvretta Capital Management Reports Acquisition of Benitec Biopharma Common Shares
Suvretta Capital Management Reports Acquisition of Benitec Biopharma Common Shares
Reuters  ·  2025-12-23
Suvretta Capital Management Reports Acquisition of Benitec Biopharma Common Shares
Benitec Biopharma Inc. held annual stockholder meeting
Reuters  ·  2025-12-03
Benitec Biopharma Inc. held annual stockholder meeting
Benitec Biopharma Is Maintained at Buy by HC Wainwright & Co.
Dow Jones  ·  2025-11-24
Benitec Biopharma Is Maintained at Buy by HC Wainwright & Co.
Benitec Biopharma Announces Pricing Of $100 Million Common Stock Offering At $13.50 Per Share
Reuters  ·  2025-11-20
Benitec Biopharma Announces Pricing Of $100 Million Common Stock Offering At $13.50 Per Share
Benitec Biopharma: Strong Financial Position and Promising Clinical Developments Justify Buy Rating
TIPRANKS  ·  2025-11-19
Benitec Biopharma: Strong Financial Position and Promising Clinical Developments Justify Buy Rating
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  2025-11-17
Calendar of U.S. Earnings Expected in the Week Ahead
Benitec Biopharma reports first quarter net loss of $9.0 million
Reuters  ·  2025-11-15
Benitec Biopharma reports first quarter net loss of $9.0 million

Introduction

Company Name.
Benitec Biopharma
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California.
Issue price:
--